Work

Repurposing TACE-induced hypoxia to activate biocatalytic hydrogen production and potentiate tirapazamine chemoimmunotherapy against hepatocellular carcinoma

Year: 2026
Type: article
Abstract: Transcatheter arterial chemoembolization (TACE) is a first-line therapy for advanced hepatocellular carcinoma (HCC), however, embolization-induced tumor hypoxia frequently promotes drug resistance and recurrence. To convert this hypoxic stress into a therapeutic opportunity, we constructed hyaluronidase-degradable hyaluronic acid (HA)-based microspheres (Sp/TPZ@Ms) co-encapsulating live Synechocystis (Sp) for biohydrogen production and tirapazamine (TPZ), a hypoxia-activated prodrug. Upon embolization, the resultant hypoxic microenvironment triggers endogenous hydrogenase-mediated H₂ generation from Sp and simultaneously activates TPZ. The evolved H₂ potentiates TPZ-induced DNA damage, eliciting robust immunogenic cell death (ICD), which subsequently promotes dendritic cell maturation and M1 polarization of tumor-associated macrophages. In vitro, Sp/TPZ@Ms under hypoxia significantly enhanced HepG2 cell killing and immune activation. In a rabbit orthotopic Vx2 HCC model, the microspheres exhibited favorable injectability, embolization performance, and HAase-responsive degradation, leading to marked tumor growth suppression and reduced pulmonary metastasis with good biosafety. This cascade strategy converts hypoxic stress into a therapeutic asset, offering a novel paradigm for TACE potentiation.
Language: English
Open Access status: gold
Estimated APC paid: $3,790
OpenAlex ID: W7222694151
FWCI:
Cites: 31
Cited by:
Related to: 10